

Figure S1. ^1H NMR spectrum of compound **1** in CDCl_3

e635 1H NMR in CDCl_3 at 400MHz Bruker AVANCEIII 400




Figure S2. ^{13}C NMR spectrum of compound **1** in CDCl_3

e635 in CDCl_3 at 100MHz Bruker AVANCEIII 400




Figure S2-2. Enlarge ^{13}C NMR spectrum of compound **1** in CDCl_3




Figure S3. DEPT spectrum of compound **1** in CDCl_3




Figure S4. HSQC spectrum of compound **1** in CDCl_3




Figure S5. ^1H - ^1H COSY spectrum of compound **1** in CDCl_3




Figure S6. HMBC spectrum of compound **1** in CDCl_3




Figure S7. NOESY spectrum of compound **1** in CDCl_3





Figure S8. HRESIMS spectrum of compound **1**

E635 #969 RT: 3.46 AV: 1 NL: 1.05E8
T: FTMS + c ESI Full ms [100.00-1000.00]

255.1945

C₁₅H₂₇O₃ = 255.1955

2.5 RDBe

-3.7311 ppm




Figure S9. IR spectrum of compound 1





Figure S10. $\text{Mo}_2(\text{AcO})_4$ -induced CD spectrum of compound **1**



[Comments]
Sample name e635-Mo
Comment

Memory-11

Figure S11. ^1H NMR spectrum of compound **2** in CDCl_3




Figure S12. ^{13}C NMR spectrum of compound **2** in CDCl_3




Figure S13. DEPT spectrum of compound **2** in CDCl_3




Figure S14. HSQC spectrum of compound **2** in CDCl_3




Figure S15. ^1H - ^1H COSY spectrum of compound **2** in CDCl_3




Figure S16. HMBC spectrum of compound **2** in CDCl_3






Figure S17. NOESY spectrum of compound **2** in CDCl_3





VNS-600 NOESYID e4314 IN cdcl3 Mar 30 2016




Figure S18. HRESIMS spectrum of compound 2




Figure S19. IR spectrum of compound 2




Figure S20. ^1H NMR spectrum of compound **3** in CDCl_3




Figure S21. ^{13}C NMR spectrum of compound **3** in CDCl_3




Figure S22. DEPT spectrum of compound **3** in CDCl_3




Figure S23. HSQC spectrum of compound **3** in CDCl_3




Figure S24. ^1H - ^1H COSY spectrum of compound **3** in CDCl_3




Figure S25. HMBC spectrum of compound **3** in CDCl_3




Figure S26. NOESY spectrum of compound **3** in CDCl_3





Figure S27. HRESIMS spectrum of compound 3

E7416211 #960 RT: 3.21 AV: 1 NL: 8.52E7
T: FTMS + c ESI Full ms [100.00-1000.00]




Figure S28. IR spectrum of compound 3




Figure S29. ^1H NMR spectrum of compound 4 in CDCl_3




Figure S30. ^{13}C NMR spectrum of compound 4 in CDCl_3




Figure S31. DEPT spectrum of compound **4** in CDCl_3




Figure S32. HSQC spectrum of compound **4** in CDCl_3




Figure S33. ^1H - ^1H COSY spectrum of compound 4 in CDCl_3




Figure S34. HMBC spectrum of compound 4 in CDCl_3





Figure S35. NOESY spectrum of compound **4** in CDCl₃






Figure S36. HRESIMS spectrum of compound 4

S85312 #1884 RT: 5.23 AV: 1 NL: 7.52E6

T: FTMS + c ESI Full ms [100.00-1000.00]

219.1736

C₁₅H₂₃O = 219.1743

4.5 RDBe

-3.5973 ppm




Figure S37. IR spectrum of compound 4





Figure S38. CD spectrum of compound 4



[Comments]
Sample name S85312

S85312-1-s-m.jws

Figure S39. ^1H NMR spectrum of compound 5 in CDCl_3




Figure S40. ^{13}C NMR spectrum of compound 5 in CDCl_3




Figure S41. DEPT spectrum of compound **5** in CDCl_3



Figure S42. HSQC spectrum of compound **5** in CDCl_3




Figure S43. ^1H - ^1H COSY spectrum of compound 5 in CDCl_3




Figure S44. HMBC spectrum of compound 5 in CDCl_3




Figure S45. NOESY spectrum of compound 5 in CDCl_3




Figure S46. HRESIMS spectrum of compound 5

E4421 #1404 RT: 4.74 AV: 1 NL: 5.25E6
T: FTMS + c ESI Full ms [100.00-1000.00]




Figure S47. IR spectrum of compound 5





Figure S48. CD spectrum of compound 5



[Comment]
Sample Name e4421

Figure S49. ¹H NMR spectrum of compound 6 in CDCl₃




Figure S50. ^{13}C NMR spectrum of compound **6** in CDCl_3




Figure S51. DEPT spectrum of compound **6** in CDCl_3




Figure S52. HSQC spectrum of compound **6** in CDCl_3




Figure S53. ^1H - ^1H COSY spectrum of compound **6** in CDCl_3




Figure S54. HMBC spectrum of compound **6** in CDCl_3






Figure S55. NOESY spectrum of compound **6** in CDCl_3



VNS-600 NOESYID e74141221 IN cdc13 Aug 23 2016



VNS-600 NOESYID e74141221 IN cdc13 Aug 25 2016




Figure S56. HRESIMS spectrum of compound 6

E74141221 #836 RT: 2.94 AV: 1 NL: 6.79E7
T: FTMS + c ESI Full ms [100.00-1000.00]




Figure S57. IR spectrum of compound 6




Figure S58. ^1H NMR spectrum of compound **7** in CDCl_3




Figure S59. ^{13}C NMR spectrum of compound **7** in CDCl_3




Figure S60. DEPT spectrum of compound **7** in CDCl_3




Figure S61. HSQC spectrum of compound **7** in CDCl_3




Figure S62. ^1H - ^1H COSY spectrum of compound **7** in CDCl_3




Figure S63. HMBC spectrum of compound **7** in CDCl_3




Figure S64. NOESY spectrum of compound **7** in CDCl_3





Figure S65. HRESIMS spectrum of compound 7

E741311 #793 RT: 2.68 AV: 1 NL: 2.78E7
T: FTMS + c ESI Full ms [100.00-1000.00]




Figure S66. IR spectrum of compound 7




Figure S67. ^1H NMR spectrum of compound 4-Benzoyl-ganodermanol G in CDCl_3




Figure S68. ^{13}C NMR spectrum of compound 4-Benzoyl-ganodermanol H in CDCl_3




Figure S69. HMBC spectrum of compound 4-Benzoyl-ganodermanol G in CDCl_3




Figure S70. ^1H NMR spectrum of compound **8** in CDCl_3

1H	2.0261	in CDCI3 at 600MHz	VNS-100
	2.0063		
	1.8834		
	1.8761		
	1.8768		
	1.7908		
	1.7985		
	1.7757		
	1.7701		
	1.7646		
	1.6230		
	1.6174		
	1.6050		
	1.6000		
	1.5956		
	1.5938		
	1.5845		
	1.5737		
	1.5678		
	1.5537		
	1.5478		
	1.4868		
	1.4805		
	1.4645		
	1.4585		
	1.4396		
	1.4356		
	1.4212		
	1.4170		
	1.4028		
	1.3981		
	1.3903		
	1.3863		
	1.3683		
	1.3641		
	1.3252		
	1.3192		
	1.3031		
	1.2973		
	1.2813		
	1.2755		
	1.2589		
	1.2483		
	1.1693		
	1.1219		
	1.0791		
	1.0791		
	1.0738		
	1.0753		
	1.0522		
	1.0352		
	1.0135		
	1.0079		
	1.0079		
	0.9946		
	0.9822		




Figure S71. ^{13}C NMR spectrum of compound **8** in CDCl_3




Figure S72. DEPT spectrum of compound **8** in CDCl_3




Figure S73. HSQC spectrum of compound **8** in CDCl_3




Figure S74. ^1H - ^1H COSY spectrum of compound **8** in CDCl_3




Figure S75. HMBC spectrum of compound **8** in CDCl_3






Figure S76. NOESY spectrum of compound **8** in CDCl_3





VNS-600 NOESY1D e7416102 IN cdc13 Jul 8 2016



VNS-600 NOESY1D e7416102 IN cdc13 Jul 8 2016




Figure S77. HRESIMS spectrum of compound 8

E7416102 #999 RT: 3.43 AV: 1 NL: 2.60E8
T: FTMS + c ESI Full ms [100.00-1000.00]




Figure S78. IR spectrum of compound 8




Figure S79. ^1H NMR spectrum of compound **9** in CDCl_3

1H NMR in CDCl₃ at 400MHz Bruker AVANCE III 400




Figure S80. ^{13}C NMR spectrum of compound **9** in CDCl_3

¹³C NMR in CDCl₃ at 400MHz Bruker AVANCEIII 400




Figure S81. DEPT spectrum of compound **9** in CDCl_3




Figure S82. HSQC spectrum of compound **9** in CDCl_3




Figure S83. ^1H - ^1H COSY spectrum of compound **9** in CDCl_3




Figure S84. HMBC spectrum of compound **9** in CDCl_3






Figure S85. NOESY spectrum of compound **9** in CDCl_3






Figure S86. HRESIMS spectrum of compound **9**

E741413 #1474 RT: 3.01 AV: 1 NL: 2.98E8
T: FTMS + c ESI Full ms [100.00-1000.00]




Figure S87. IR spectrum of compound 9




Figure S88. ¹H NMR spectrum of compound 10 in CDCl₃




Figure S89. ^{13}C NMR spectrum of compound **10** in CDCl_3




Figure S90. DEPT spectrum of compound **10** in CDCl_3




Figure S91. HSQC spectrum of compound **10** in CDCl_3




Figure S92. ^1H - ^1H COSY spectrum of compound **10** in CDCl_3




Figure S93. HMBC spectrum of compound **10** in CDCl_3





Figure S94. NOESY spectrum of compound **10** in CDCl_3







Figure S95. HRESIMS spectrum of compound **10**

E7413121 #788 RT: 2.71 AV: 1 NL: 5.16E7

T: FTMS + c ESI Full ms [100.00-1000.00]

219.1736

C₁₅H₂₃O = 219.1743

4.5 RDBE

-3.5973 ppm




Figure S96. IR spectrum of compound **10**




Figure S97. ^1H NMR spectrum of compound **11** in CDCl_3




Figure S98. ^{13}C NMR spectrum of compound **11** in CDCl_3




Figure S98-2. Enlarge ^{13}C NMR spectrum of compound **11** in CDCl_3




Figure S99. DEPT spectrum of compound **11** in CDCl_3




Figure S100. HSQC spectrum of compound **11** in CDCl_3




Figure S101. ^1H - ^1H COSY spectrum of compound **11** in CDCl_3




Figure S102. HMBC spectrum of compound **11** in CDCl_3





Figure S103. NOESY spectrum of compound **11** in CDCl_3







Figure S104. HRESIMS spectrum of compound 11

e74153 #1004 RT: 3.07 AV: 1 NL: 7.54E7
T: FTMS + c ESI Full ms [100.00-1000.00]




Figure S105. IR spectrum of compound 11




Figure S106. ^1H NMR spectrum of compound **11** in $\text{DMSO}-d_6$




Figure S107. ^{13}C NMR spectrum of compound **11** in $\text{DMSO}-d_6$





Figure S108. HMBC spectrum of compound **11** in $\text{DMSO}-d_6$



^1H NMR and ^{13}C NMR data of Compounds **11**



positio n	11^a			11^b		
	δ_c	type	δ_h (<i>J</i> in Hz)	δ_c	type	δ_h (<i>J</i> in Hz)
1	74.3, CH		3.88, dd (11.3, 4.9)	71.8, CH		3.63, dt (11.3, 4.8)
2	26.5, CH_2		1.66, m, $\text{H}\alpha$ 1.71, m, $\text{H}\beta$	26.4, CH_2		1.57, m, $\text{H}\alpha^c$ 1.59, m, $\text{H}\beta^c$
3	26.9, CH_2		2.20, m, $\text{H}\alpha$ 1.37, m, $\text{H}\beta$	26.6, CH_2		2.10, m, $\text{H}\alpha$ 1.07, m, $\text{H}\beta^c$
4	41.4, CH		1.53, m	40.2, CH		1.47, m
5	77.6, C			75.4, C		
6	33.8, CH_2		1.84, m, $\text{H}\alpha$ 1.30, m, $\text{H}\beta$	33.1, CH_2		1.74, m, $\text{H}\alpha^c$ 1.20, m, $\text{H}\beta^c$
7	43.3, CH		1.85, m	42.3, CH		1.77, m
8	21.7, CH_2		1.65, m, $\text{H}\alpha$ 1.32, m, $\text{H}\beta$	21.1, CH_2		1.55, m, $\text{H}\alpha^c$ 1.22, m, $\text{H}\beta^c$
9	33.3, CH_2		1.72, m, $\text{H}\alpha$ 1.57, m, $\text{H}\beta$	32.8, CH_2		1.78, m, $\text{H}\alpha$ 1.49, m, $\text{H}\beta^c$
10	42.7, C			41.2, C		
11	72.9, C			70.7, C		
12	28.0, CH_3		1.22, s	27.6, CH_3		1.04, s
13	27.0, CH_3		1.20, s	27.4, CH_3		1.02, s
14	15.6, CH_3		1.00, s	15.5, CH_3		0.82, s
15	16.9, CH_3		1.04, d (7.7)	16.8, CH_3		0.93, d (7.7)
1-OH						3.92, d (5.3)
5-OH						3.32, s
11-OH						3.86, s

^aData were recorded at 400 MHz for proton and at 100 MHz for carbon in CDCl₃.

^bData were recorded at 400 MHz for proton and at 100 MHz for carbon in DMSO-d₆.

^cOverlapped with other signals.

Figure S109. NOESY spectrum of compound **11** in DMSO-d₆






Table S1

Cytotoxicities of isolated compounds against five human cancer cell lines (IC_{50} , μM).

Compounds	IC_{50}					
		HCT116	NCI-H1650	BGC823	Daoy	HepG2
1	>50.0	>50.0	>50.0	>50.0	>50.0	>50.0
2	>50.0	>50.0	>50.0	>50.0	>50.0	>50.0
3	24.5	>50.0	>50.0	>50.0	>50.0	>50.0
4	16.6	>50.0	49.9	31.1	27.9	
5	>50.0	>50.0	>50.0	>50.0	>50.0	>50.0
6	>50.0	28.9	>50.0	35.5	>50.0	
7	>50.0	>50.0	>50.0	>50.0	>50.0	
8	>50.0	>50.0	>50.0	>50.0	>50.0	
9	12.2	>50.0	>50.0	>50.0	>50.0	
10	>50.0	>50.0	>50.0	>50.0	>50.0	
11	>50.0	>50.0	>50.0	>50.0	>50.0	
12	>50.0	>50.0	>50.0	>50.0	>50.0	
13	>50.0	>50.0	>50.0	>50.0	>50.0	
14	>50.0	>50.0	>50.0	>50.0	>50.0	
Paclitaxel	0.000809	0.945	0.00177	0.00933	0.0249	

Table S2Anti-HIV-1 activity of isolated compounds (IC_{50} , μM).

Compounds	HIV-1
1	NA
2	NA
3	NA
4	37.9
5	NA
6	NA
7	NA
8	NA
9	NA
10	NA
11	NA
12	NA
13	NA
14	NA
Efavirenz	0.002

NA=No activity